Cyxone AB (publ) (CYXO.ST)
SEK 0.02
(0.0%)
SEK 0.02
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 4.69 Million SEK | -15.89% |
| 2022 | 5.58 Million SEK | -19.07% |
| 2021 | 6.89 Million SEK | 36.64% |
| 2020 | 5.04 Million SEK | 49.41% |
| 2019 | 3.37 Million SEK | -34.04% |
| 2018 | 5.12 Million SEK | 30.21% |
| 2017 | 3.93 Million SEK | 438.52% |
| 2016 | 730.28 Thousand SEK | 128.22% |
| 2015 | 320 Thousand SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 4.23 Million SEK | -9.71% |
| 2024 Q2 | 3.46 Million SEK | -18.31% |
| 2023 Q1 | 6.15 Million SEK | 10.34% |
| 2023 FY | 4.69 Million SEK | -15.89% |
| 2023 Q4 | 4.69 Million SEK | 3.69% |
| 2023 Q3 | 4.52 Million SEK | -27.76% |
| 2023 Q2 | 6.26 Million SEK | 1.77% |
| 2022 Q1 | 12.34 Million SEK | 78.94% |
| 2022 Q2 | 5.92 Million SEK | -51.99% |
| 2022 Q3 | 8 Million SEK | 35.02% |
| 2022 Q4 | 5.58 Million SEK | -30.24% |
| 2022 FY | 5.58 Million SEK | -19.07% |
| 2021 FY | 6.89 Million SEK | 36.64% |
| 2021 Q1 | 3.98 Million SEK | -20.96% |
| 2021 Q3 | 5.39 Million SEK | 5.44% |
| 2021 Q2 | 5.11 Million SEK | 28.15% |
| 2021 Q4 | 6.89 Million SEK | 27.94% |
| 2020 Q2 | 6.27 Million SEK | 83.82% |
| 2020 Q1 | 3.41 Million SEK | 0.98% |
| 2020 Q4 | 5.04 Million SEK | -75.37% |
| 2020 FY | 5.04 Million SEK | 49.41% |
| 2020 Q3 | 20.48 Million SEK | 226.78% |
| 2019 FY | 3.37 Million SEK | -34.04% |
| 2019 Q4 | 3.37 Million SEK | -23.38% |
| 2019 Q3 | 4.4 Million SEK | 19.65% |
| 2019 Q2 | 3.68 Million SEK | 32.51% |
| 2019 Q1 | 2.78 Million SEK | -45.69% |
| 2018 Q2 | 2.36 Million SEK | -33.86% |
| 2018 Q1 | 3.57 Million SEK | -9.2% |
| 2018 FY | 5.12 Million SEK | 30.21% |
| 2018 Q4 | 5.12 Million SEK | 27.99% |
| 2018 Q3 | 4 Million SEK | 69.39% |
| 2017 FY | 3.93 Million SEK | 438.52% |
| 2017 Q1 | 604 Thousand SEK | -17.29% |
| 2017 Q2 | 1.51 Million SEK | 150.17% |
| 2017 Q3 | 1.44 Million SEK | -4.17% |
| 2017 Q4 | 3.93 Million SEK | 171.6% |
| 2016 Q2 | 3.11 Million SEK | 0.0% |
| 2016 FY | 730.28 Thousand SEK | 128.22% |
| 2016 Q3 | 570 Thousand SEK | -81.7% |
| 2016 Q4 | 730.28 Thousand SEK | 28.12% |
| 2015 FY | 320 Thousand SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| 2cureX AB (publ) | 2.93 Million SEK | -59.932% |
| Abliva AB (publ) | 16.78 Million SEK | 72.028% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | 63.167% |
| AcouSort AB (publ) | 10.37 Million SEK | 54.77% |
| Active Biotech AB (publ) | 13.4 Million SEK | 64.97% |
| Alzinova AB (publ) | 9.33 Million SEK | 49.695% |
| Amniotics AB (publ) | 10.54 Million SEK | 55.494% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | 40.949% |
| Aptahem AB (publ) | 8.99 Million SEK | 47.832% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -6.055% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 95.596% |
| BioInvent International AB (publ) | 90.45 Million SEK | 94.811% |
| BioArctic AB (publ) | 139.5 Million SEK | 96.635% |
| Biosergen AB | 5.08 Million SEK | 7.689% |
| Biovica International AB (publ) | 34.76 Million SEK | 86.499% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | 70.875% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 99.7% |
| Camurus AB (publ) | 414.81 Million SEK | 98.868% |
| Cantargia AB (publ) | 54.97 Million SEK | 91.461% |
| Corline Biomedical AB | 6.78 Million SEK | 30.859% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -22.303% |
| CombiGene AB (publ) | 4.15 Million SEK | -12.945% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | 35.344% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 93.4% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 97.813% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | 65.915% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | 64.781% |
| Fluicell AB (publ) | 8.91 Million SEK | 47.347% |
| Genovis AB (publ.) | 98.04 Million SEK | 95.213% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | 74.619% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 99.604% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 89.835% |
| Mendus AB (publ) | 51.22 Million SEK | 90.837% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 92.35% |
| Isofol Medical AB (publ) | 19.16 Million SEK | 75.506% |
| I-Tech AB | 16.2 Million SEK | 71.034% |
| Intervacc AB (publ) | 21.68 Million SEK | 78.349% |
| Kancera AB (publ) | 17.97 Million SEK | 73.89% |
| Karolinska Development AB (publ) | 11.56 Million SEK | 59.426% |
| LIDDS AB (publ) | 3.75 Million SEK | -24.973% |
| Lipum AB (publ) | 7.53 Million SEK | 37.729% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | 8.996% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 96.214% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -98.983% |
| Nanologica AB (publ) | 79.32 Million SEK | 94.083% |
| NextCell Pharma AB | 13.68 Million SEK | 65.71% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 97.415% |
| OncoZenge AB (publ) | 1.69 Million SEK | -176.28% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -161.65% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 82.425% |
| Saniona AB (publ) | 86.08 Million SEK | 94.547% |
| Simris Alg AB (publ) | 148.93 Million SEK | 96.848% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | 59.77% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | 86.435% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | 9.643% |
| SynAct Pharma AB | 51.83 Million SEK | 90.944% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 88.512% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 99.026% |
| Xintela AB (publ) | 14.01 Million SEK | 66.507% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 93.467% |
| Ziccum AB (publ) | 6.38 Million SEK | 26.518% |